03:21 , Nov 17, 2018 |  BioCentury  |  Product Development

Betting Combos on Biomarkers

Despite lackluster monotherapy data at SITC from the latest tranche of immunotherapy candidates, drug developers are moving into combination trials with PD-1 and PD-L1 inhibitors based on biomarkers of pharmacodynamic activity. Results from the next...
00:18 , Nov 17, 2018 |  BC Extra  |  Preclinical News

Spotlight co-founder uses CRISPR screen to ID T cell regulator genes for cancer

Spotlight Therapeutics Inc. (Hayward, Calif.) co-founder Alexander Marson and colleagues at University of California San Francisco developed a CRISPR-based screen to identify genes that control T cell replication and immunosuppression, and used the results to...
22:38 , Nov 1, 2018 |  BC Extra  |  Company News

Management tracks: CuraSen names Vargas CMO; plus Sosei, Casebia

Neurodegenerative disease start-up CuraSen Therapeutics Inc. (San Mateo, Calif.) hired Gabriel Vargas as its first CMO. Vargas led early development of migraine prophylactic Aimovig erenumab at Amgen Inc. (NASDAQ:AMGN), where he was most recently executive...
22:59 , Oct 26, 2018 |  BioCentury  |  Emerging Company Profile

Karius: Blood will tell

Karius Inc. is diagnosing both blood-borne and deep-seated infections with its Karius Test, which sequences cell-free microbial DNA in blood samples and cuts the run time required in traditional assays. The company spun out of...
18:03 , Oct 25, 2018 |  BC Innovations  |  Distillery Techniques

Disease models

TECHNOLOGY: Animal models Mice expressing a TBR1 mutation could be useful for screening therapies to treat autism. Mice engineered to harbor a cortical layer 6 neuron-specific loss-of-function mutation on TBR1 -- deletion of exons 2...
17:40 , Oct 19, 2018 |  BC Week In Review  |  Company News

Revolution acquiring Warp Drive

Revolution Medicines Inc. (Redwood City, Calif.) is expanding its cancer pipeline with the acquisition of another Third Rock Ventures portfolio company, Warp Drive Bio Inc. (Cambridge, Mass.). The financial terms of the deal are undisclosed...
22:17 , Oct 16, 2018 |  BC Extra  |  Company News

Revolution acquiring fellow Third Rock company Warp Drive

Revolution Medicines Inc. (Redwood City, Calif.) is expanding its cancer pipeline with the acquisition of another Third Rock Ventures portfolio company, Warp Drive Bio Inc. (Cambridge, Mass.). The financial terms of the deal are undisclosed...
20:27 , Oct 12, 2018 |  BioCentury  |  Finance

Spinning out Sitryx

With a $30 million series A round and a pipeline of immunometabolism programs, Sitryx Therapeutics Ltd. became the first start-up to emerge from the Immunology Network at GlaxoSmithKline plc (LSE:GSK; NYSE:GSK). The round, which closed...
18:13 , Oct 12, 2018 |  BC Week In Review  |  Financial News

Immunometabolism company Sitryx debuts with GSK ties, $30M

Sitryx Therapeutics Ltd. (Oxford, U.K.) emerged from stealth on Oct. 8 with $30 million from a series A round to develop disease-modifying therapeutics for immuno-oncology and immuno-inflammation, which CEO Neil Weir expects to be enough...
21:37 , Oct 8, 2018 |  BC Extra  |  Financial News

Immunometabolism company Sitryx debuts with GSK ties, $30M

Sitryx Therapeutics Ltd. (Oxford, U.K.) emerged from stealth on Monday with $30 million from a series A round to develop disease-modifying therapeutics for immuno-oncology and immuno-inflammation, which CEO Neil Weir expects to be enough runway...